Scarica l'app Stockscreener
23.63
0.38%
-0.09
Dopo l'orario di chiusura:
24.00
0.37
+1.57%
Precedente Chiudi:
$23.72
Aprire:
$24.01
Volume 24 ore:
927.29K
Relative Volume:
0.88
Capitalizzazione di mercato:
$2.09B
Reddito:
-
Utile/perdita netta:
$-151.78M
Rapporto P/E:
-11.47
EPS:
-2.0595
Flusso di cassa netto:
$-136.42M
1 W Prestazione:
-8.62%
1M Prestazione:
-18.63%
6M Prestazione:
-12.38%
1 anno Prestazione:
-41.60%
Intervallo 1D:
$23.55
$24.34
Intervallo di 1 settimana:
$23.55
$25.95
Portata 52W:
$22.30
$47.65
Mineralys Therapeutics Inc Stock (MLYS) Company Profile
Nome
Mineralys Therapeutics Inc
Settore
Industria
Telefono
(888) 378-6240
Indirizzo
150 N. RADNOR CHESTER RD., RADNOR
Compare MLYS vs VRTX, MRNA, REGN, ARGX, RVMD
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
MLYS
Mineralys Therapeutics Inc
|
23.63 | 2.29B | 0 | -151.78M | -136.42M | -2.0595 |
VRTX
Vertex Pharmaceuticals Inc
|
504.73 | 133.37B | 12.34B | 4.34B | 3.71B | 16.87 |
MRNA
Moderna Inc
|
190.01 | 79.40B | 2.23B | -3.19B | -1.60B | -8.1462 |
REGN
Regeneron Pharmaceuticals Inc
|
735.20 | 81.13B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
919.21 | 60.03B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
206.64 | 43.93B | 742.00K | -1.37B | -1.07B | -7.0731 |
Mineralys Therapeutics Inc Stock (MLYS) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-04-27 | Iniziato | TD Cowen | Buy |
| 2025-06-11 | Iniziato | Jefferies | Hold |
| 2024-07-10 | Iniziato | H.C. Wainwright | Buy |
| 2024-04-02 | Iniziato | Goldman | Buy |
| 2023-03-07 | Iniziato | BofA Securities | Buy |
| 2023-03-07 | Iniziato | Credit Suisse | Outperform |
| 2023-03-07 | Iniziato | Evercore ISI | Outperform |
| 2023-03-07 | Iniziato | Guggenheim | Buy |
| 2023-03-07 | Iniziato | Stifel | Buy |
| 2023-03-07 | Iniziato | Wells Fargo | Overweight |
Mostra tutto
Mineralys Therapeutics Inc Borsa (MLYS) Ultime notizie
Mineralys Therapeutics Announces Presentation of - GlobeNewswire
Mineralys Therapeutics, Inc. (MLYS) Stock Price, News, Quote & History - Yahoo! Finance Canada
Form 144 Mineralys Therapeutics For: 1 October By Investing.com - Investing.com Canada
A 75,000-share sale is proposed by a Mineralys (MLYS) officer and director. - Stock Titan
Two new hires at Mineralys receive options on 46,430 shares and stock awards tied to 34,823 shares. - Stock Titan
Mineralys Therapeutics (MLYS) Faces A Fresh Valuation Test On New Lorundrostat Data - Yahoo Finance
Mineralys to Present Long-Term Lorundrostat Data in November - MyChesCo
Form 144 MINERALYS THERAPEUTICS For: 27 September By Investing.com - Investing.com India
Mineralys Sets Investor Forum Appearance as Lorundrostat Advances - MyChesCo
Form 4 Mineralys Therapeutics Inc For: 24 September By Investing.com - Investing.com Canada
Mineralys Therapeutics director sells $3 million in shares By Investing.com - Investing.com Nigeria
Mineralys Therapeutics director sells $3 million in shares - Investing.com
A fund sold Mineralys (MLYS) shares and still holds more than 7.8 million. - Stock Titan
Mineralys Therapeutics to Participate in the Stifel 2026 Virtual Cardiometabolic Forum - GlobeNewswire
Mineralys to present lorundrostat trial data at AHA meeting By Investing.com - Investing.com Canada
Mineralys to present lorundrostat trial data at AHA meeting - Investing.com India
Mineralys Therapeutics’ Transform-HTN Open-Label Extension Trial Data Selected for Late-Breaking Presentation at American Heart Association Scientific Sessions 2026 - The Manila Times
Mineralys Therapeutics’ Transform-HTN Open-Label Extension - GlobeNewswire
Form 144 Mineralys Therapeutics For: 23 September By Investing.com - Investing.com Nigeria
Form 4 Mineralys Therapeutics Inc For: 22 September By Investing.com - Investing.com Canada
Mineralys Therapeutics CCO Eric Warren sells $209k in stock - Investing.com India
Mineralys Therapeutics CCO Eric Warren sells $209k in stock By Investing.com - Investing.com Nigeria
Mineralys Therapeutics (MLYS) CCO sells 7,438 shares in pre-set plan - Stock Titan
Fund may sell Mineralys (NASDAQ: MLYS) shares; filing shows the size - Stock Titan
(MLYS) Risk Channels and Responsive Allocation - Stock Traders Daily
Mineralys Therapeutics, Inc. (MLYS) Stock Analysis: A Promising 71% Upside Potential In Biotech - DirectorsTalk Interviews
Mineralys Therapeutics (MLYS) officer lines up new stock option sale - Stock Titan
A new employee gets Mineralys stock awards covering 14,880 and 11,160 shares - Stock Titan
Mineralys Therapeutics director Karydas sells $85,740 in stock By Investing.com - Investing.com Canada
Mineralys Therapeutics director Karydas sells $85,740 in stock - Investing.com
Mineralys Therapeutics (MLYS) director sells shares under preset plan - Stock Titan
Mineralys Therapeutics (NASDAQ: MLYS) executive plans new stock option sale after recent $388K trade - Stock Titan
Mineralys (NASDAQ: MLYS) officer to sell 3,000 shares via options - Stock Titan
Mineralys Grants Equity Awards to Two New Employees - mychesco.com
Mineralys (MLYS) officer to sell 7,709 shares - Stock Titan
Understanding the Setup: (MLYS) and Scalable Risk - Stock Traders Daily
Mineralys Therapeutics grants inducement equity awards covering 52,080 shares to new hires - Bitget
Mineralys at Wells Fargo conference: lorundrostat launch takes shape By Investing.com - Investing.com Canada
MLYS: Lorundrostat nears approval with strong data, broad market prep, and a focus on parity access - TradingView
Mineralys Therapeutics (NASDAQ: MLYS) insider to sell 2,171 shares via cashless option exercise - Stock Titan
Two new hires get four-year stock awards from Mineralys - Stock Titan
Mineralys Therapeutics Market Sentiment - Benzinga España
BEAM Stock Price and Chart — NASDAQ:BEAM - TradingView
Mineralys Therapeutics upgraded to Buy ahead of lorundrostat FDA approval and strong market launch. - Pluang
Mineralys: Why I'm Making Stock A Buy Ahead Of Hypertension Approval Decision (MLYS) - Seeking Alpha
Mineralys Therapeutics to Participate in the Wells Fargo 21st Annual Healthcare Conference - Yahoo Finance
Mineralys Therapeutics CCO Eric Warren sells $193,188 in shares By Investing.com - Investing.com Nigeria
Mineralys (NASDAQ: MLYS) CCO sells 7,437 shares under 10b5-1 plan - Stock Titan
Mineralys Therapeutics Inc Azioni (MLYS) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Mineralys Therapeutics Inc Azioni (MLYS) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Slingsby Brian Taylor | Director |
Sep 22 '26 |
Sale |
28.81 |
104,320 |
3,005,303 |
7,805,718 |
| Warren Eric | Chief Commercial Officer |
Sep 21 '26 |
Option Exercise |
13.24 |
7,438 |
98,479 |
45,838 |
| Warren Eric | Chief Commercial Officer |
Sep 21 '26 |
Sale |
28.12 |
7,438 |
209,136 |
38,400 |
0.05%
0.82%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):